NCT05741905 Safety and Efficacy of Levofloxacin Combined With Intravenous Thrombolysis for Acute Ischemic Stroke
| NCT ID | NCT05741905 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Yi Yang |
| Condition | Acute Ischemic Stroke |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2023-06-01 |
| Primary Completion | 2024-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2023-06-01 with a primary completion date of 2024-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to determine the efficacy and safety of levofloxacin combined with intravenous thrombolysis in treating acute ischemic stroke
Eligibility Criteria
Inclusion Criteria: 1. Age 18-75 years. 2. Acute ischemic stroke patients underwent intravenous thrombolysis, treated with ateplase (0.9mg/kg) 3. mRS≤1 before stroke onset, NIHSS ≥ 5 and ≤ 15，la (NIHSS) level of consciousness \< 1 Exclusion Criteria: 1. Endovascular treatment 2. Patients using glucocorticoids, antiarrhythmic drugs (class I and class III antiarrhythmic drugs: quinidine, procaine amine, lidocaine, phenytoin sodium, verapamil, etc.), and quinolones within 14 days; 3. Patients with other diseases that may aggravate adverse drug reactions, such as ventricular arrhythmias, prolonged QT interval (male: QTc\>430ms, female: QTc\>450ms), severe cardiac insufficiency (NYHA functional grade ≥ III), myasthenia gravis, peripheral neuropathy, seizures, tendon-related diseases, severe immune system-related diseases, hematological diseases, active hepatitis or cirrhosis, serious respiratory diseases; 4. Abnormal liver and kidney function: glutamic oxaloacetic transaminase or glutamic pyruvic transaminase exceeds 3 times the upper limit of normal; Direct bilirubin or indirect bilirubin more than 3 times the normal upper limit; Blood creatinine exceeds 1.1 times the upper limit of normal; Creatinine clearance rate≤50ml/min; Urea nitrogen≥ 20mg/dL; 5. Concurrent infection; 6. Fasting blood glucose lower than 3.9 mmol/L; 7. Patients with symptomatic intracranial hemorrhage confirmed by clinical signs and imaging before randomization; 8. Patients allergy to fluoroquinolones or other antibiotics; 9. Patients with a life expectancy less than 3 months or patients unable to complete the study for other reasons; 10. Not willing to be followed up or poor treatment compliance; 11. Patients who are participating in other clinical studies, or have participated in other clinical studies within 3 months before enrollment, or have participated in this study; 12. Other conditions not suitable for enrollment.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05741905 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Acute Ischemic Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05741905 currently recruiting?
Yes, NCT05741905 is actively recruiting participants. Contact the research team at doctoryangyi@163.com for enrollment information.
Where is the NCT05741905 trial being conducted?
This trial is being conducted at Changchun, China.
Who is sponsoring the NCT05741905 clinical trial?
NCT05741905 is sponsored by Yi Yang. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.